Innovent's IBI3003 Shows Promising Efficacy in Multiple Myeloma Clinical Trials
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 1 hour ago0mins
- Clinical Trial Progress: Innovent's IBI3003 presented at the ASH Annual Meeting shows an objective response rate of 83.3% at doses ≥120 μg/kg, indicating its potential in treating relapsed or refractory multiple myeloma.
- Patient Demographics: Among the 39 enrolled patients, 64.1% were classified as high-risk, and 46.2% had extramedullary disease (EMD), highlighting IBI3003's efficacy in addressing urgent clinical needs in high-risk populations.
- Treatment Optimization: IBI3003 is administered subcutaneously once weekly, with the option for patients achieving partial response to switch to biweekly maintenance after ≥6 months, aiming to enhance patient adherence and treatment outcomes.
- Safety and Tolerability: Despite the relatively short follow-up, IBI3003 demonstrated favorable tolerability and a manageable safety profile, particularly in high-risk patients, suggesting a promising outlook for its broader application in future therapies.
01801.HK
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on 01801
Wall Street analysts forecast 01801 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01801 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 92.000
Low
Averages
High
Current: 92.000
Low
Averages
High
CCBI
CCBI
Outperform
maintain
$125 -> $128
2025-11-07
Reason
CCBI
CCBI
Price Target
$125 -> $128
2025-11-07
maintain
Outperform
Reason
The analyst rating for INNOVENT BIO was influenced by several positive factors highlighted in the article. The company's total product revenue for 3Q25 grew by over 40% year-over-year, exceeding expectations and surpassing the broker's full-year growth forecast of 37%. Additionally, the revenue increased by 22% quarter-over-quarter, which was a faster pace compared to the previous year.
CCBI, the research firm, views INNOVENT BIO as a leader in China's biologics market for treating challenging chronic and fatal diseases, prompting them to raise their revenue forecasts for the company for 2025-27. They also increased the adjusted earnings forecasts for the same period. As a result of these strong performance indicators and positive outlook, CCBI raised the target price for INNOVENT BIO from HKD 125 to HKD 128 while maintaining an "Outperform" rating.
CMBI
CMBI
Buy
maintain
2025-10-24
Reason
CMBI
CMBI
Price Target
2025-10-24
maintain
Buy
Reason
The analyst rating for INNOVENT BIO was maintained at "Buy" due to the announcement of a global strategic partnership with Takeda Pharmaceutical, which includes significant upfront payments and potential milestone payments that enhance the company's financial outlook. CMBI expressed optimism about the global development of key oncology assets IBI363 and IBI343, leading to an increase in the target price from $109.48 to $110.62 based on the discounted cash flow (DCF) method.
JPMorgan
JPMorgan
maintain
$114 -> $110
2025-10-23
Reason
JPMorgan
JPMorgan
Price Target
$114 -> $110
2025-10-23
maintain
Reason
The analyst rating for INNOVENT BIO was reaffirmed as "Overweight" by JPMorgan due to the company's recent global collaboration agreement with Takeda Pharmaceutical, which includes a significant upfront payment and potential milestone payments. This agreement is seen as a strategic move that strengthens INNOVENT BIO's market position in the US and enhances its capabilities for independent global clinical development and commercialization. Despite trimming the target price from $114 to $110, the overall outlook remains positive, leading to the continued endorsement as a top pick in China's biopharma sector.
CLSA
CLSA
upgrade
2025-10-23
Reason
CLSA
CLSA
Price Target
2025-10-23
upgrade
Reason
The analyst rating for INNOVENT BIO was influenced by the positive outlook stemming from its global strategic collaboration with Takeda Pharmaceutical. CLSA viewed this partnership favorably for INNOVENT BIO's global expansion and product development, particularly in advancing the core project IBI363. As a result of this collaboration, CLSA raised its sales and net profit forecasts significantly for FY26 and made a slight increase for FY27. Consequently, the target price for INNOVENT BIO was increased, and the Outperform rating was maintained.
See All Ratings
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?